With aging, fibrinogen transcytosed via caveolin-1 into the perivascular space, exacerbating Aβ buildup. Elevated fibrinogen disrupted aquaporin-4 function. Depleting fibrinogen rescued CAA, ...

Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Missense mutations that derail SORL1 trafficking cause AD. Other variants shift AD risk in East Asians and Europeans. SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

The two new deaths seem to be of the third category. At baseline, the APOE4 homozygote at Columbia had one microhemorrhage on MRI, and no signs of CAA, and appeared to be a good candidate for the ...

In diseases driven by dysfunctional microglia, could replacing them with healthy versions prevent, or even reverse, pathology? Yes, suggest two papers in the June 18 Neuron. Both describe how mice ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...